BRPI0712004A2 - inibiÇço mediada pela interferÊncia do rna da auroraquinase b e de suas combinaÇÕes como terapia anticÂncer - Google Patents
inibiÇço mediada pela interferÊncia do rna da auroraquinase b e de suas combinaÇÕes como terapia anticÂncerInfo
- Publication number
- BRPI0712004A2 BRPI0712004A2 BRPI0712004-4A2A BRPI0712004A BRPI0712004A2 BR PI0712004 A2 BRPI0712004 A2 BR PI0712004A2 BR PI0712004 A BRPI0712004 A BR PI0712004A BR PI0712004 A2 BRPI0712004 A2 BR PI0712004A2
- Authority
- BR
- Brazil
- Prior art keywords
- aurorakinase
- rna
- combinations
- mediated inhibition
- anticancer therapy
- Prior art date
Links
- 102000004228 Aurora kinase B Human genes 0.000 title 1
- 108090000749 Aurora kinase B Proteins 0.000 title 1
- 102000014150 Interferons Human genes 0.000 title 1
- 108010050904 Interferons Proteins 0.000 title 1
- 238000011319 anticancer therapy Methods 0.000 title 1
- 230000005764 inhibitory process Effects 0.000 title 1
- 229940079322 interferon Drugs 0.000 title 1
- 230000001404 mediated effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/11—Protein-serine/threonine kinases (2.7.11)
- C12Y207/11001—Non-specific serine/threonine protein kinase (2.7.11.1), i.e. casein kinase or checkpoint kinase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Botany (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN974MU2006 | 2006-06-21 | ||
| PCT/IN2007/000251 WO2008035365A2 (en) | 2006-06-21 | 2007-06-21 | Rna interference mediated inhibition of aurorakinase b and its combinations as anticancer therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0712004A2 true BRPI0712004A2 (pt) | 2013-09-17 |
Family
ID=39051006
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0712004-4A2A BRPI0712004A2 (pt) | 2006-06-21 | 2007-06-21 | inibiÇço mediada pela interferÊncia do rna da auroraquinase b e de suas combinaÇÕes como terapia anticÂncer |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US7615627B2 (enExample) |
| EP (1) | EP2037940B1 (enExample) |
| JP (1) | JP2009541304A (enExample) |
| AU (1) | AU2007298506B2 (enExample) |
| BR (1) | BRPI0712004A2 (enExample) |
| IL (1) | IL195943A0 (enExample) |
| RU (1) | RU2009101785A (enExample) |
| WO (1) | WO2008035365A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009114703A2 (en) * | 2008-03-12 | 2009-09-17 | Fox Chase Cancer Center | Combination therapy for the treatment of cancer |
| WO2012034942A1 (en) | 2010-09-13 | 2012-03-22 | Santaris Pharma A/S | Compounds for the modulation of aurora kinase b expression |
| US9226936B2 (en) | 2011-10-28 | 2016-01-05 | The Wistar of Anatomy and Biology | Methods and compositions for enhancing the therapeutic effect of anti-tumor T cells |
| WO2014204024A1 (ko) * | 2013-06-18 | 2014-12-24 | 한국원자력의학원 | Hs2st1 유전자 또는 상기 유전자가 암호화하는 단백질에 대한 억제제를 포함하는 세포 노화 유도용 조성물 및 이를 이용한 세포 노화 유도 방법 |
| KR101734308B1 (ko) | 2015-01-21 | 2017-05-12 | 한국과학기술연구원 | siRNA 표적-특이적 전달을 위한 RNA/DNA 나노입자 및 이를 포함하는 전달체 |
| CN117757789A (zh) * | 2022-09-26 | 2024-03-26 | 领星生物科技（上海）有限公司 | 用于抑制肿瘤生长的siRNA及其应用 |
| CN116173059B (zh) * | 2022-12-16 | 2024-11-05 | 福州载基生物科技有限公司 | 人aurkb基因在制备抗肿瘤药物中的用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5734039A (en) * | 1994-09-15 | 1998-03-31 | Thomas Jefferson University | Antisense oligonucleotides targeting cooperating oncogenes |
| WO2002090514A2 (en) | 2001-05-07 | 2002-11-14 | Hybridon, Inc. | Epidermal growth factor receptorantisense oligonucleotides |
| MY141867A (en) | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
| WO2004070062A2 (en) * | 2003-02-04 | 2004-08-19 | Wyeth | Compositions and methods for diagnosing and treating cancers |
| JP2005278472A (ja) | 2004-03-29 | 2005-10-13 | Pharma Design Inc | オーロラｂ結合因子ｉｎｃｅｎｐ |
| US7375212B2 (en) | 2004-05-24 | 2008-05-20 | Isis Pharmaceuticals, Inc. | Modulation of Aurora B expression |
-
2007
- 2007-06-19 US US11/812,513 patent/US7615627B2/en not_active Expired - Fee Related
- 2007-06-21 RU RU2009101785/15A patent/RU2009101785A/ru not_active Application Discontinuation
- 2007-06-21 AU AU2007298506A patent/AU2007298506B2/en not_active Ceased
- 2007-06-21 JP JP2009516068A patent/JP2009541304A/ja active Pending
- 2007-06-21 EP EP07859578A patent/EP2037940B1/en not_active Not-in-force
- 2007-06-21 BR BRPI0712004-4A2A patent/BRPI0712004A2/pt not_active IP Right Cessation
- 2007-06-21 WO PCT/IN2007/000251 patent/WO2008035365A2/en not_active Ceased
-
2008
- 2008-12-15 IL IL195943A patent/IL195943A0/en not_active IP Right Cessation
-
2009
- 2009-09-25 US US12/567,423 patent/US8026225B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20100285107A1 (en) | 2010-11-11 |
| IL195943A0 (en) | 2009-09-01 |
| US8026225B2 (en) | 2011-09-27 |
| WO2008035365A8 (en) | 2009-07-23 |
| JP2009541304A (ja) | 2009-11-26 |
| WO2008035365A3 (en) | 2008-07-31 |
| AU2007298506B2 (en) | 2012-04-05 |
| WO2008035365A2 (en) | 2008-03-27 |
| US20080038189A1 (en) | 2008-02-14 |
| EP2037940B1 (en) | 2013-02-13 |
| EP2037940A2 (en) | 2009-03-25 |
| US7615627B2 (en) | 2009-11-10 |
| AU2007298506A1 (en) | 2008-03-27 |
| RU2009101785A (ru) | 2010-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0923283A2 (pt) | conjugados terapêuticos de peptídeo e usos dos mesmos | |
| BRPI0821779A2 (pt) | tratamento terapêutico de câncer | |
| BRPI0912225A2 (pt) | peptídeos de direcionamento lisossomais e usos dos mesmos | |
| BR112012004149A2 (pt) | terapia de combinação com composições de nanopartículas de taxano e inibidores de hedgehog | |
| EP2002263A4 (en) | IMMUNOTHERAPY COMPOSITIONS FOR CANCER AND METHODS OF USE | |
| PT2963031T (pt) | Pró-fármacos de tetrahidrocanabinol, composições compreendendo pró-fármacos de tetrahidrocanabinol e métodos de utilização dos mesmos | |
| IL214396A (en) | Anti-viral anti-viral nucleosides, pharmaceutical preparations containing them and methods for their preparation, as well as their preparation of antiviral intermediates | |
| FR2949470B1 (fr) | Derives anticancereux, leur preparation et leur application therapeutique | |
| ZA200902084B (en) | Combination therapy with SGLT-2 inhibitors and their pharmaceutical compositions | |
| BRPI0919322A2 (pt) | derivados de glicosideo e usos dos mesmos como inibidores sglt | |
| IL197315A0 (en) | Treatment of cancer | |
| EP2136846A4 (en) | THERAPEUTIC OBJECTIVES AND MOLECULES | |
| BR112012001260A2 (pt) | conjugados de epsilon-polilisina e o emprego dos mesmos | |
| BRPI0821383A2 (pt) | Conjugados de ngf e usos dos mesmos | |
| GB0718167D0 (en) | Cancer marker and therapeutic target | |
| EP2534174A4 (en) | Preparation and / or purification of oligonucleotide conjugates | |
| BRPI0712004A2 (pt) | inibiÇço mediada pela interferÊncia do rna da auroraquinase b e de suas combinaÇÕes como terapia anticÂncer | |
| PL2523946T3 (pl) | Tricykliczne seskwiterpenowe laktony do stosowania w leczeniu otyłości i związanych chorób i stanów możliwych do leczenia nieterapeutycznego | |
| BR112012005774A2 (pt) | terapia anticancerígena de combinação do vaccinia vírus oncolítico | |
| EP2124910A4 (en) | ANTITUMOR THERAPY BY TARGETING EWS-FLI1 | |
| ZA200908100B (en) | Treatment and prevention of influenza | |
| BRPI0916043A2 (pt) | composição farmacêutica e alimento funcional para prevenir ou tratar câncer | |
| BRPI0920743A2 (pt) | ribonucleases terapeuticas | |
| BRPI0812932A2 (pt) | Composições e métodos de tratar câncer | |
| EP2349325A4 (en) | PROTECTION AND REPAIR OF CARTILAGINOUS AND MUSCULOSKELETAL SOFT TISSUES |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE 4A., 5A. E 6A. ANUIDADE(S). |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2226 DE 03-09-2013 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |